DDInter1094 DDInter1435
Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Lorlatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Lorlatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acetohexamide
Lorlatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Betrixaban
Lorlatinib {u} may lead to a major life threatening interaction when taken with {v} Venetoclax
Lorlatinib {u} may lead to a major life threatening interaction when taken with {v} Lurbinectedin
Lorlatinib may cause a minor interaction that can limit clinical effects when taken with Lidocaine
Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide
Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Lorlatinib may lead to a major life threatening interaction when taken with Venetoclax
Lorlatinib may lead to a major life threatening interaction when taken with Lurbinectedin